Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Upadacitinib effectively treats pyoderma gangrenosum.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Finasteride may help treat female hair loss, but has risks.

JAK1 inhibitors can help reduce itchiness in atopic dermatitis.

Trastuzumab may cause tufted hair folliculitis as a side effect.

A patient with complete hair loss regrew all her hair using tofacitinib.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Abrocitinib may effectively treat Lichen Planopilaris.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

New probes were created to effectively measure specific enzymes involved in fat metabolism, which could help develop new drugs.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

New acne treatments show promise as alternatives to traditional therapies.

Cytochrome P-450 enzymes in the skin help break down various substances and could be targeted to treat skin conditions.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

The TRPV3 ion channel is important for skin and hair health and could be a target for treating skin conditions.

UV exposure harms skin by causing fibroblast loss, but T cells help fibroblast survival.

Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.